[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Zhongshan People's Hospital, Guangdong, China\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":169},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,51,79,102,124,146],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100515395","smartphone-based-remote-symptom-monitoring-to-improve-postoperative-rehabilitation-exercise-adherence-after-video-assisted-thoracic-surgery-vats-for-lung-cancer-100515395",false,"NCT05990946","Smartphone-based Remote Symptom Monitoring to Improve Postoperative Rehabilitation Exercise Adherence After Video-assisted Thoracic Surgery (VATS) for Lung Cancer","A Prospective, Randomized, Controlled Study to Evaluate the Impact of Remote Symptom Management Via Smartphone App Based on Electronic Patient-Reported Outcomes on Rehabilitation Exercise Adherence After Minimally Invasive Surgery in Lung Cancer Patients","Inclusion Criteria:\n\n* Age 18-75 years old\n* Undergoing minimally invasive lung cancer resection\n* Able to use smartphones and complete electronic questionnaires\n* Signed informed consent\n\nExclusion Criteria:\n\n* conversions to open thoracotomy during surgery\n* ECOG score \\> 1\n* Received neoadjuvant therapy\n* Previous lung resection surgery\n* Unable to exercise due to physical limitations\n* Continuous systemic corticosteroid use within 1 month before enrollment\n* Unresolved toxicity above Grade 1 from previous treatments\n* Significant comorbidities or medical history","ALL","18 Years","75 Years",{"count":20,"type":21},736,"ESTIMATED","INTERVENTIONAL",[24],"NA","Brief Summary: This randomized controlled trial aims to evaluate whether active remote symptom monitoring and management via a smartphone app utilizing electronic patient-reported outcomes (ePRO) can improve adherence to prescribed outpatient pulmonary rehabilitation exercises among postsurgical lung cancer patients. Eligible patients will use the app for perioperative care and be randomized to an intervention group receiving ePRO-based symptom monitoring with clinician feedback or a control group receiving ePRO without feedback. The primary outcome is rehabilitation exercise adherence rate over 1 month after discharge. If proven effective, the app-enabled remote rehabilitation model can be scaled up to enhance recovery for more postoperative patients.\n\nDue to slower-than-expected recruitment, an interim analysis was introduced through a protocol amendment. The amendment was approved by the Ethics Committee before conducting the analysis, and the plan was incorporated into the updated study record. The interim review evaluated feasibility and informed the addition of mean weekly exercise duration as a co-primary endpoint with adjusted statistical thresholds.",[27,28,29,30,31],"Lung Neoplasms, Non-Small Cell Lung Cancer","Postoperative Complications","Patient Reported Outcome Measures","Telerehabilitation","Exercise Therapy",[33,34,35,36,37],"Exercise Adherence","ePRO","Remote Monitoring","Postoperative Rehabilitation","Symptom Management","RECRUITING","2025-11-27",{"date":41,"type":42},"2025-12-05","ACTUAL",{"date":44,"type":42},"2023-06-01",{"date":46,"type":21},"2026-06-30",{"name":48,"class":49},"Zhongshan People's Hospital, Guangdong, China","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":16,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":62,"studyType":63,"phases":4,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":50},"100507253","screening-effect-of-dual-energy-ct-combined-with-nasopharyngeal-endoscopy-for-screening-nasopharyngeal-carcinoma-100507253","NCT05884983","Screening Effect of Dual-energy CT Combined With Nasopharyngeal Endoscopy for Screening Nasopharyngeal Carcinoma","Inclusion Criteria:\n\n* Subject residents in Zhongshan City\n* Subject has no medical record of nasopharyngeal carcinoma\n* Subject is able to comprehend, sign, and date the written informed consent document to participate in the study\n* Subject has psychical condition and well consciousness, and also accept and cooperate with the follow-up of this study\n\nExclusion Criteria:\n\n* Subject has heavy cardiovascular, liver or kidney disease\n* Subject has contraindications to nasopharyngeal endoscopy\n* Subject has contrast media allergy",true,"30 Years","69 Years",{"count":61,"type":21},12000,"6 Months","OBSERVATIONAL","All participants will be tested for EBV-related biomarkers, including EBNA1-IgA, VCA-IgA, and BNLF2b total antibody (P85-Ab), and participants with high serologic risk will be selected based on serologic test results, and dual-energy CT will be performed first for high-risk screening subjects, and dual-energy CT will be performed first for the high-risk group to record dual-energy CT examinations of those suspected of nasopharyngeal carcinoma, and then endoscopy was performed on the high-risk group to record those suspected of nasopharyngeal carcinoma under endoscopy, and finally biopsies were taken for positive lesion sites indicated by dual-energy CT and suspicious lesion sites found by endoscopy to clarify the diagnosis.",[66],"Nasopharyngeal Carcinoma",[68,66,69,70],"Screening","Dual-energy CT","Endoscopy","2025-08-11",{"date":73,"type":42},"2025-08-15",{"date":75,"type":42},"2023-02-01",{"date":77,"type":21},"2026-12-31",{"name":48,"class":49},{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":57,"sex":16,"minAge":85,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":50},"100593727","head-to-head-comparison-of-hepatocellular-cancer-hcc-screening-strategies-a-prospective-population-based-cohort-study-in-zhongshan-city-100593727","NCT07010198","Head-to-Head Comparison of Hepatocellular Cancer (HCC) Screening Strategies: A Prospective Population-Based Cohort Study in Zhongshan City","Inclusion Criteria:\n\n* Voluntarily sign the informed consent form.\n* Household registration in Zhongshan City, Guangdong Province.\n* Aged 35 and above.\n* Positive screening result for Hepatitis B surface antigen (HBsAg).\n\nExclusion Criteria:\n\n* Previous history of liver cancer or liver transplantation.\n* Pregnant women.\n* Severe comorbidities (e.g., end-stage cardiopulmonary diseases, advanced malignancies).\n* Individuals lacking legal capacity or unable to provide informed consent.","35 Years",{"count":87,"type":21},4500,"Based on the preliminary retrospective validation of the efficacy of five HCC screening strategies(including conventional AFP combined with ultrasound-based general screening strategy, REACH-B, AGED, aMAPand aMAP 3.0 risk score) in Xiaolan Town, a head-to-head comparison for HCC screening is conducted in Zhongshan City, Guangdong Province. The study is a prospective, single-center, head-to-head trial aiming to enroll 4,500 HBsAg-positive individuals. It adopts a two-phase design of \"HBV screening first, followed by HCC surveillance\":Phase I: Recruitment of age-eligible populations at study sites for HBsAg screening to establish a high-risk cohort positive for hepatitis B surface antigen.Phase II: Implementation of uniform HCC surveillance (AFP combined with liver ultrasound every six months) for HBsAg-positive individuals, with concurrent application of different risk stratification models to evaluate risk levels and screening efficacy for each participant during follow-up.Furthurmore, based on baseline biological information and follow-up data, the study also aims to explore the development of a more effective risk prediction model for HCC.",[90],"Hepatocellular Cancer (HCC)",[68,92,93],"Hepatocellular Cancer","aMAP","2025-05-29",{"date":96,"type":42},"2025-06-08",{"date":98,"type":42},"2025-03-01",{"date":100,"type":21},"2028-12-31",{"name":48,"class":49},{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":112,"briefSummary":113,"conditions":114,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":50},"100537797","xerostomia-optimised-imrt-versus-standard-imrt-in-npc-100537797","NCT06282497","Xerostomia-optimised IMRT Versus Standard IMRT in NPC","Xerostomia-optimised Intensity-modulated Radiotherapy Versus Standard Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma Patients:a Multicenter Non-inferior Randomized Controlled Phase III Clinical Trial","Inclusion Criteria:\n\n* Newly histologic diagnosis of nasopharyngeal non-keratinizing carcinoma (WHO II\u002FIII);\n* All genders, range from 18-70 years old;\n* ECOG score 0-1;\n* Clinical stage I-IVa (AJCC\u002FUICC 8th);\n* Not received radiotherapy, chemotherapy and other anti-tumor treatment (including immunotherapy);\n* No contraindications to chemotherapy or radiotherapy;\n* Adequate organ function: white blood cell count ≥ 4×109\u002FL, neutrophile granulocyte count ≥ 1.5×109\u002FL, hemoglobin ≥ 90g\u002FL, platelet count ≥ 100×109\u002FL; alanine aminotransferase or aspartate aminotransferase \\\u003C 2.5×upper limit of normal; blood urea nitrogen or creatinine ≤ 1.5×upper limit of normal or endogenous creatinine clearance ≥ 60ml\u002Fmin (Cockcroft-Gault formula);\n* Sign the consent form.\n\nExclusion Criteria:\n\n* Level II involvement with extracapsular extension (ECE), and\u002For had a maximum nodal axial diameter (MAD) of greater than 3cm in level II ;\n\n  -≥4 nodal regions of ipsilateral neck involvement;\n* Radiologically suspicious or confirmed involvement in level II area between skull base and the lateral process of C1;\n* Parotid lymph node and\u002For parotid gland involvement;\n* History of parotid disease or surgery;\n* Previous malignancy or other concomitant malignant disease;\n* Pregnancy or lactation.","70 Years",{"count":111,"type":21},524,[24],"This is a multi-center, non-inferiority, open-label, randomized controlled phase III clinical trial in primary diagnosed nasopharyngeal carcinoma (NPC) patients without distant metastasis. This study aims to compare the regional control, survival outcomes, radiation-related toxicities, and quality of life (QoL) of xerostomia-optimized intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in NPC patients",[115],"Nasopharyngeal Carcinoma ,Xerostomia,Radiotherapy","2024-04-28",{"date":118,"type":42},"2024-05-01",{"date":120,"type":42},"2023-10-23",{"date":122,"type":21},"2029-10-23",{"name":48,"class":49},{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":109,"enrollmentInfo":132,"targetDuration":4,"studyType":22,"phases":134,"briefSummary":135,"conditions":136,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":50},"100515643","reducing-high-risk-primary-tumor-clinical-target-volumes-ctvp1-in-non-metastatic-nasopharyngeal-carcinoma-100515643","NCT05994170","Reducing High Risk Primary Tumor Clinical Target Volumes (CTVp1) in Non-metastatic Nasopharyngeal Carcinoma","Reducing High Risk Primary Tumor Clinical Target Volumes (CTVp1) in Non-metastatic Nasopharyngeal Carcinoma Treated With Intensity-modulated Radiotherapy(IMRT): A Phase 3, Multicentre, Randomised Controlled Trial(CTVp1-NPC)","CTVp1-NPC","Inclusion Criteria:\n\n1. histologic confirmation of nonkeratinizing nasopharyngeal carcinoma(WHO II-III);\n2. newly diagnosed stage I to IVa according to the American Joint Committee on Cancer-Union for International Cancer Control 8th edition stage-classification system\n3. nasopharyngeal mass confined to one side of nasopharynx and did not exceed the midline(the line between the nasal septum and the midpoint of spinal cord\u002Fmedulla) detected by electronic nasopharyngoscope (ENS) and magnetic resonance imaging (MRI). Pathological biopsy was recommended if it was unclear whether tumor invaded the contralateral side radiographically.\n4. planned to receive curative IMRT, Chemotherapy drugs should be administered according to Chinese Society of Clinical Oncology (CSCO) guidelines depending on the TNM stage;(T1N0: No chemotherapy required;T2N0：No chemotherapy or concurrent cisplatin chemoradiotherapy if there are adverse prognostic indicators such as Epstein-Barr virus (EBV) DNA\\>4000 copies，node \\>3cm or with extranodal extension;T1-2N1: concurrent cisplatin chemoradiotherapy;T3N0: concurrent cisplatin chemoradiotherapy; stage III-Iva: platinum-based neoadjuvant chemotherapy+ concurrent cisplatin chemoradiotherapy+\u002F-metronomic capecitabine therapy )\n5. no previous treatment for cancer；\n6. a Karnofsky performance-status score of at least 70 (on a scale from 0 to 100, with lower scores indicating greater disability);\n7. between 18 and 70 years old;\n8. adequate hematologic, renal, and hepatic function: Adequate marrow function: WBC count ≥ 3×10E9\u002FL, NE count ≥ 1.5×10E9\u002FL, HGB ≥ 90g\u002FL, PLT count ≥ 100×10E9\u002FL;Adequate liver function: ALT and AST ≤ 2.5×ULN, TBIL ≤ 2.0×ULN;Adequate renal function: BUN and CRE ≤ 1.5×ULN , endogenous creatinine clearance ≥ 60ml\u002Fmin (Cockcroft-Gault formula);\n9. Patients must be informed of the investigational nature of this study and give written informed consent.\n\nExclusion Criteria:\n\n1. receipt of treatment with palliative intent;\n2. receipt of previous treatment (radiotherapy, chemotherapy, or surgery \\[except diagnostic procedures\\]) to the nasopharynx;\n3. had disease progress after neoadjuvant chemotherapy in local advantage NPC\n4. presence of distant metastasis;\n5. Keratinized squamous cell carcinoma or basal cell like squamous cell carcinoma;\n6. Prior malignancy except adequately treated non-melanoma skin cancer, in situ cervical cancer, and papillary thyroid carcinoma;\n7. Have New York Heart Association (NYHA) class 3 or 4, unstable angina, myocardial -infarction within 1 year, or clinically meaningful arrhythmia that requires treatment;\n8. lactation or pregnancy;\n9. Any other condition including Mental disorder,drug or alcohol addition;do not have full capacity for civil acts.",{"count":133,"type":21},454,[24],"To evaluate the long-term local control, survival rate, acute and late radiation related toxicities, quality of life after reducing high risk primary tumor clinical target volumes (CTVp1) in non-metastatic nasopharyngeal carcinoma treated with IMRT.",[66,137],"Intensity-Modulated Radiotherapy","2023-08-08",{"date":140,"type":42},"2023-08-16",{"date":142,"type":42},"2023-08-04",{"date":144,"type":21},"2029-09-01",{"name":48,"class":49},{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":57,"sex":16,"minAge":58,"maxAge":59,"enrollmentInfo":153,"targetDuration":155,"studyType":63,"phases":4,"briefSummary":156,"conditions":157,"keywords":158,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":168},"100369098","screening-nasopharyngeal-carcinoma-with-ebv-associated-biomarkers-in-zhongshan-city-100369098","NCT04085900","Screening Nasopharyngeal Carcinoma With EBV Associated Biomarkers in Zhongshan City","Searching for Early Detection Biomarkers of Nasopharyngeal Carcinoma in Zhongshan City","Inclusion Criteria:\n\n* Subject residents in Zhongshan City or Wuzhou City\n* Subject has no medical record of nasopharyngeal carcinoma\n* ECOG 0-2\n* Subject is able to comprehend, sign, and date the written informed consent document to participate in the study.\n* Subject has psychical condition and well consciousness, and also accept and cooperate with the follow-up of this study.\n\nExclusion Criteria:\n\n* Subject has heavy cardiovascular, liver or kidney disease.\n* Subject has contraindications to nasopharyngeal fiberoptic endoscopy.",{"count":154,"type":21},40000,"5 Years","All participants will be tested for EBV associated biomarkers, including EBNA1-IgA, VCA-IgA, BNLF2b total antibodies (P85-Ab) et al. For all male participants and P85-Ab positive female participants, EBV DNA in plasma will be tested. Screening positive participants will be followed up annually.\n\nAll subjects will also be followed by record linkage to Cancer Register and Population Register.",[66],[68,66,159],"Biomarker","2023-07-12",{"date":162,"type":42},"2023-07-13",{"date":164,"type":42},"2020-04-01",{"date":166,"type":21},"2027-12-31",{"name":48,"class":49},2,""]